Shire Presents Positive Data from Fabry and Gaucher Disease Studies that Continue to Support Patient Switches to REPLAGAL and VPRIV

Shire plc SHPGY today announced positive data from several studies designed to evaluate the safety of switching to REPLAGAL (agalsidase alfa) from Fabrazyme® (agalsidase beta) and the long-term safety and benefits of switching to VPRIV (velaglucerase alfa) from Cerezyme® (imiglucerase). Study results are being presented at the 2011 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism held from August 30 – September 2 in Geneva, Switzerland.